Can't Miss Webinar—Lupus Nephritis: The ACR Guideline in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: infliximab

Mucosal Healing Seen with Infliximab Biosimilar CT-P13 in Ulcerative Colitis

Reuters Staff  |  

NEW YORK (Reuters Health)—About two-thirds of patients with ulcerative colitis (UC) had mucosal healing by the end of induction treatment with the infliximab biosimilar CT-P13, according to results of the first prospective study to evaluate this. CT-P13 is the first biosimilar monoclonal antibody of reference infliximab (Remicade) approved in Europe and several other countries where…

FDA Update: Infliximab Biosimilar Garners Support & Fibromyalgia Drug Receives Fast Track

  |  

Recently, an FDA committee announced support for the approval of CT-P13, an infliximab biosimilar. The FDA has also fast tracked the development of a fibromyalgia treatment designed for multiple symptoms…

Studies Challenge Conventional Infliximab Protocols in IBD

Laura Newman  |  

NEW YORK (Reuters Health)—Dose optimization of infliximab is needed much earlier in ulcerative colitis than in Crohn’s disease, a single-center retrospective study reveals. “We compared the rates of dose increases over a fairly lengthy period of time,” said Dr. Mark Silverberg, the study’s senior author from the Mount Sinai Hospital in Toronto. “Patients with ulcerative…

RA Research Presented at ACR Convergence 2025 in Focus

Jeffrey Curtis, MD, MS, MPH  |  

This synopsis of research into rheumatoid arthritis highlights key areas presented at ACR Convergence 2025, including strategies to delay or prevent RA, emerging mechanisms of action in RA treatment, and the growing role of AI in advancing RA research and clinical care.